Home LiteratureArticle Details
PMID: 3515312 Published · ppublish English Journal Article Review

Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.

Pharmaceutisch weekblad. Scientific edition ·Vol. 8 ·No. 1 ·1986-02-21 ·Pages 1-21

Janknegt R

Abstract

Quinolones, chemically related to nalidixic acid, have a strong and rapid bactericidal action against Gram-negative bacteria, including Ps. aeruginosa, some Mycobacteria, Legionella and Staphylococci. Streptococci and anaerobic bacteria are usually less sensitive. The quinolones exert their bactericidal action through inhibition of the enzyme DNA gyrase. Quinolones are absorbed for 50-100% from the gastro-intestinal tract, their volume of distribution is generally high (2 l/kg) and high concentrations are reached in almost all organs. The elimination half-lives range from 4 to 14 h. The efficacy of quinolones in urinary tract infections has been shown in many studies. They also seem to be effective in many serious infections. In animal studies their efficacy was generally equal or superior to aminoglycosides. Until now only mild and infrequent side effects have been reported.

MeSH Terms
Animals Anti-Bacterial Agents/pharmacology Bacteria, Anaerobic/drug effects Chemical Phenomena Chemistry Digestive System/microbiology Drug Interactions Drug Resistance, Microbial Gram-Negative Bacteria/drug effects Gram-Positive Bacteria/drug effects Humans Kinetics Microbial Sensitivity Tests Quinolines/metabolism,pharmacology,therapeutic use Structure-Activity Relationship
Chemicals
Anti-Bacterial Agents Quinolines
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Janknegt R
References (98)
98 references, click to expand
  1. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
    J Antimicrob Chemother. 1984 Mar;13(3):237-44 PMID: 6586712
  2. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:63-9 PMID: 6389476
  3. Reduced enteral absorption of ciprofloxacin in the presence of antacids.
    Eur J Clin Microbiol. 1985 Jun;4(3):345 PMID: 3160584
  4. Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae.
    Infection. 1983 Nov-Dec;11(6):326-8 PMID: 6421743
  5. Open, prospective study of the clinical efficacy of ciprofloxacin.
    Antimicrob Agents Chemother. 1985 Jul;28(1):128-32 PMID: 2931046
  6. Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function--some preliminary results.
    J Antimicrob Chemother. 1984 May;13 Suppl B:55-7 PMID: 6234276
  7. Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients.
    J Antimicrob Chemother. 1984 May;13 Suppl B:79-83 PMID: 6234279
  8. The pharmacokinetics and tissue penetration of norfloxacin.
    J Antimicrob Chemother. 1984 Jan;13(1):87-92 PMID: 6230344
  9. Activities of newer quinolones against Legionella group organisms.
    Lancet. 1983 Jul 30;2(8344):279-80 PMID: 6135099
  10. In vitro activities of the spectinomycin analog U-63366 and four quinolone derivatives against Neisseria gonorrhoeae.
    Antimicrob Agents Chemother. 1984 Oct;26(4):608-9 PMID: 6240224
  11. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    J Antimicrob Chemother. 1984 Apr;13(4):325-31 PMID: 6233249
  12. Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa.
    J Infect Dis. 1985 Feb;151(2):291-4 PMID: 3155780
  13. Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin.
    Antimicrob Agents Chemother. 1985 Mar;27(3):350-2 PMID: 3158273
  14. Enoxacin raises plasma theophylline concentrations.
    Lancet. 1984 Jul 14;2(8394):108-9 PMID: 6145999
  15. Ciprofloxacin distribution in prostatic tissue and fluid following oral administration.
    Chemotherapy. 1985;31(1):13-8 PMID: 3156024
  16. Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections.
    J Antimicrob Chemother. 1984 May;13 Suppl B:113-20 PMID: 6234271
  17. In vitro and in vivo antibacterial activities of the fluoroquinolone WIN 49375 (amifloxacin).
    Antimicrob Agents Chemother. 1985 Jan;27(1):4-10 PMID: 3885845
  18. Resistance to ciprofloxacin.
    Lancet. 1985 Jul 6;2(8445):39 PMID: 2861478
  19. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.
    Antimicrob Agents Chemother. 1983 Aug;24(2):302-4 PMID: 6227281
  20. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.
    Eur J Clin Microbiol. 1984 Aug;3(4):355-9 PMID: 6489326
  21. Intraprostatic concentrations of ciprofloxacin after intravenous administration.
    Lancet. 1984 Sep 22;2(8404):695-6 PMID: 6147717
  22. Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis.
    Antimicrob Agents Chemother. 1985 Sep;28(3):428-32 PMID: 2934021
  23. [Ciprofloxacine: evaluation of its biliary elimination in man].
    Schweiz Med Wochenschr. 1985 Mar 30;115(13):448-53 PMID: 3158073
  24. Assessment of the in vitro and in vivo activity of ciprofloxacin measured against current standards of therapy.
    Drugs Exp Clin Res. 1985;11(5):343-50 PMID: 2941263
  25. In vitro activities of the quinolone antimicrobial agents A-56619 and A-56620.
    Antimicrob Agents Chemother. 1985 Oct;28(4):514-20 PMID: 3935046
  26. Efficacy and safety of ciprofloxacin (Bay 0 9867) in the treatment of patients with complicated urinary tract infections.
    J Antimicrob Chemother. 1985 Aug;16(2):211-7 PMID: 2933381
  27. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:33-8 PMID: 6238931
  28. Norfloxacin in acute urinary tract infections.
    Practitioner. 1984 Jan;228(1387):111-7 PMID: 6229726
  29. Control of burn wound infections by pefloxacin and its silver derivative.
    Burns Incl Therm Inj. 1984 Feb;10(3):170-8 PMID: 6586256
  30. Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase.
    Proc Natl Acad Sci U S A. 1976 Dec;73(12):4474-8 PMID: 794878
  31. Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.
    Drugs. 1984 Jun;27(6):548-78 PMID: 6376062
  32. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.
    Antimicrob Agents Chemother. 1984 Mar;25(3):331-5 PMID: 6721464
  33. In vitro activity of ciprofloxacin (Bay o 9867).
    Antimicrob Agents Chemother. 1983 Oct;24(4):568-74 PMID: 6228192
  34. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.
    Antimicrob Agents Chemother. 1984 May;25(5):633-7 PMID: 6233935
  35. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora.
    J Infect Dis. 1985 Jul;152(1):104-7 PMID: 3159811
  36. Dose- and sex-independent disposition of ciprofloxacin.
    Eur J Clin Microbiol. 1984 Aug;3(4):363-6 PMID: 6489328
  37. Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.
    Eur J Clin Microbiol. 1983 Dec;2(6):548-53 PMID: 6230226
  38. In vitro activity of ciprofloxacin against mycobacteria.
    Eur J Clin Microbiol. 1985 Jun;4(3):345-7 PMID: 3160585
  39. Comparative in-vitro activity of quinolone carboxylic acids against Proteeae.
    J Antimicrob Chemother. 1984 Nov;14(5):485-9 PMID: 6511707
  40. In vitro activity of ciprofloxacin, azthreonam and ceftazidime against Serratia marcescens and Pseudomonas aeruginosa.
    Eur J Clin Microbiol. 1984 Aug;3(4):368-9 PMID: 6436021
  41. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA.
    Proc Natl Acad Sci U S A. 1985 Jan;82(2):307-11 PMID: 2982149
  42. Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens.
    Antimicrob Agents Chemother. 1984 Apr;25(4):504-6 PMID: 6732220
  43. Effects of changes in pH, medium, and inoculum size on the in vitro activity of amifloxacin against urinary isolates of Staphylococcus saprophyticus and Escherichia coli.
    Antimicrob Agents Chemother. 1985 Apr;27(4):449-51 PMID: 3890724
  44. Amifloxacin activity against well-defined gentamicin-resistant, gram-negative bacteria.
    Antimicrob Agents Chemother. 1984 Nov;26(5):781-4 PMID: 6440481
  45. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.
    Antimicrob Agents Chemother. 1984 Dec;26(6):797-801 PMID: 6098219
  46. Dose-dependent pharmacokinetic study of pefloxacin, a new antibacterial agent, in humans.
    J Pharm Sci. 1984 Oct;73(10):1379-82 PMID: 6594505
  47. Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.
    Eur J Clin Microbiol. 1984 Aug;3(4):333-8 PMID: 6237901
  48. In vitro activity of ciprofloxacin against Bacteroides, Haemophilus influenzae and Branhamella catarrhalis.
    Eur J Clin Microbiol. 1984 Aug;3(4):370-1 PMID: 6333337
  49. Comparative activity of ciprofloxacin against anaerobic bacteria.
    Antimicrob Agents Chemother. 1985 Mar;27(3):427-8 PMID: 3158278
  50. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
    Drugs Exp Clin Res. 1985;11(5):335-8 PMID: 2941261
  51. DNA gyrase: an enzyme that introduces superhelical turns into DNA.
    Proc Natl Acad Sci U S A. 1976 Nov;73(11):3872-6 PMID: 186775
  52. Pharmacokinetics of norfloxacin in renal failure.
    J Antimicrob Chemother. 1984 Oct;14(4):439 PMID: 6238930
  53. Quinolones and raised plasma concentrations of theophylline.
    Lancet. 1984 Sep 1;2(8401):530 PMID: 6147598
  54. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.
    Antimicrob Agents Chemother. 1984 Mar;25(3):319-26 PMID: 6232895
  55. Activity of the newer quinolones against Chlamydia trachomatis.
    Br J Vener Dis. 1984 Oct;60(5):350 PMID: 6487989
  56. Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis.
    Antimicrob Agents Chemother. 1984 Sep;26(3):289-91 PMID: 6594970
  57. Enoxacin: worldwide in-vitro activity against 22451 clinical isolates.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:47-55 PMID: 6594322
  58. A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.
    Eur J Clin Microbiol. 1984 Aug;3(4):328-32 PMID: 6237900
  59. Comparison of the in vitro activities of ofloxacin and tetracycline against Chlamydia trachomatis as assessed by indirect immunofluorescence.
    Antimicrob Agents Chemother. 1984 Jul;26(1):13-6 PMID: 6383207
  60. The pharmacokinetics and tissue penetration of ofloxacin.
    J Antimicrob Chemother. 1984 Dec;14(6):647-52 PMID: 6596301
  61. Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria.
    Antimicrob Agents Chemother. 1984 Mar;25(3):342-3 PMID: 6721466
  62. [Comparison of the antimicrobial activity of pefloxacin (1589 RB), nalidixic acid and flumequin (author's transl)].
    Pathol Biol (Paris). 1982 Jun;30(6):394-7 PMID: 6810283
  63. Activity of ciprofloxacin against genital tract pathogens.
    Br J Vener Dis. 1984 Oct;60(5):316-8 PMID: 6435814
  64. In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.
    Antimicrob Agents Chemother. 1983 May;23(5):658-63 PMID: 6223577
  65. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.
    Antimicrob Agents Chemother. 1984 Nov;26(5):757-61 PMID: 6517559
  66. In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin.
    Antimicrob Agents Chemother. 1984 Mar;25(3):377-9 PMID: 6326666
  67. Mutational resistance to 4-quinolone antibacterial agents.
    Eur J Clin Microbiol. 1984 Aug;3(4):347-50 PMID: 6237904
  68. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new beta-lactams.
    J Antimicrob Chemother. 1985 Jan;15(1):39-44 PMID: 3156112
  69. Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora.
    Antimicrob Agents Chemother. 1984 Oct;26(4):481-4 PMID: 6240223
  70. Pharmacokinetics and tissue penetration of ciprofloxacin.
    Antimicrob Agents Chemother. 1983 Nov;24(5):784-6 PMID: 6660852
  71. Nalidixic acid: an antibacterial paradox.
    Antimicrob Agents Chemother. 1975 Sep;8(3):251-61 PMID: 1101818
  72. [The antibacterial activity in vitro of ofloxacin in comparison with other orally administered antimicrobial substances on ampicillin-resistant clinical isolates].
    Arzneimittelforschung. 1984;34(11):1552-4 PMID: 6596953
  73. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.
    Antimicrob Agents Chemother. 1983 Apr;23(4):559-64 PMID: 6222695
  74. Pharmacokinetics of ciprofloxacin after oral and parenteral administration.
    Antimicrob Agents Chemother. 1985 Mar;27(3):375-9 PMID: 3158275
  75. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
    Antimicrob Agents Chemother. 1983 Nov;24(5):754-63 PMID: 6229216
  76. In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
    J Antimicrob Chemother. 1984 Apr;13(4):333-46 PMID: 6233250
  77. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
    Eur J Clin Microbiol. 1983 Apr;2(2):111-5 PMID: 6222896
  78. Comparative in vitro studies with 4-quinolone antimicrobials.
    Drugs Exp Clin Res. 1985;11(5):317-29 PMID: 2941259
  79. Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.
    Antimicrob Agents Chemother. 1984 Apr;25(4):463-72 PMID: 6587830
  80. Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.
    Antimicrob Agents Chemother. 1985 Apr;27(4):657-9 PMID: 3847273
  81. Pharmacokinetics of intravenously administered ciprofloxacin.
    Antimicrob Agents Chemother. 1984 Aug;26(2):208-10 PMID: 6486762
  82. In vitro activities of ciprofloxacin, norfloxacin, pipemidic acid, cinoxacin, and nalidixic acid against Chlamydia trachomatis.
    Antimicrob Agents Chemother. 1984 Jan;25(1):123-4 PMID: 6230988
  83. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
    Chemotherapy. 1985;31(1):19-28 PMID: 3156025
  84. Clinical resistance to long-term oral ciprofloxacin.
    Lancet. 1985 Jun 1;1(8440):1275 PMID: 2860471
  85. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers.
    Antimicrob Agents Chemother. 1984 Nov;26(5):741-4 PMID: 6517556
  86. Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens.
    J Antimicrob Chemother. 1984 Dec;14(6):641-5 PMID: 6440885
  87. Norfloxacin versus cotrimoxazole in the treatment of uncomplicated urinary tract infections--a multi-centre trial.
    J Antimicrob Chemother. 1984 May;13 Suppl B:89-94 PMID: 6234281
  88. The treatment of Pseudomonas aeruginosa urinary tract infections with norfloxacin.
    J Antimicrob Chemother. 1984 May;13 Suppl B:85-8 PMID: 6234280
  89. In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives.
    Antimicrob Agents Chemother. 1984 Apr;25(4):518-21 PMID: 6732221
  90. The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro.
    Eur J Clin Microbiol. 1984 Aug;3(4):344-6 PMID: 6237903
  91. The pharmacokinetics and tissue penetration of enoxacin and norfloxacin.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:75-81 PMID: 6238932
  92. Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships.
    J Med Chem. 1984 Sep;27(9):1103-8 PMID: 6381730
  93. In vitro activity of enoxacin compared with norfloxacin and amikacin.
    Eur J Clin Microbiol. 1985 Feb;4(1):55-8 PMID: 3157568
  94. Multiple-dose ciprofloxacin kinetics in normal subjects.
    Clin Pharmacol Ther. 1984 Sep;36(3):384-8 PMID: 6467798
  95. Susceptibility of Legionella spp. to quinolone derivatives and related organic acids.
    Eur J Clin Microbiol. 1984 Aug;3(4):373 PMID: 6489330
  96. In vitro activity of amifloxacin against Chlamydia trachomatis and Ureaplasma urealyticum.
    Eur J Clin Microbiol. 1985 Oct;4(5):515-6 PMID: 4065142
  97. Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens.
    Antimicrob Agents Chemother. 1985 Mar;27(3):388-92 PMID: 3158276
  98. In-vitro activity of enoxacin against aminoglycoside-resistant gram-negative bacilli and other clinical isolates.
    J Antimicrob Chemother. 1984 Sep;14 Suppl C:1-6 PMID: 6438046
Article Info
Journal
Pharmaceutisch weekblad. Scientific edition
Abbr.
Pharm Weekbl Sci
ISSN
0167-6555
Published
1986-02-21
Pages
1-21
Language
English
Region
Netherlands
NLM ID
7907992
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com